Most Read Articles
6 days ago
A strong belief in the necessity of medication is associated with better adherence to oral disease-modifying antirheumatic drugs (DMARDs) or prednisone, while higher self-efficacy correlates with poor adherence, in a diverse cohort of patients with rheumatoid arthritis (RA), suggests a study.
5 days ago
Low-dose administrations of haloperidol after thoracic surgery does not appear to prevent postoperative delirium, according to a new study.
3 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 4 days ago
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.

Rituximab may induce remission, allow glucocorticoid tapering in IgAV

06 Dec 2017

Rituximab appears to be safe and effective in the treatment of patients with adult-onset IgA vasculitis (IgAV), inducing disease remission and allowing glucocorticoid tapering, according to a study.

The multicentre, observational study included 22 patients with adult-onset IgAV (formerly Henoch-Schönlein purpura) who had received rituximab for either refractory/relapsing disease or due to contraindications to conventional glucocorticoid/immunosuppressive therapy. The median follow-up was 24 months.

Researchers estimated the rates of remission (defined on the basis of the Birmingham Vasculitis Activity Score, BVAS) and relapse, as well as the variations over time in estimated glomerular filtration rate (eGFR), proteinuria, C-reactive protein levels, BVAS and prednisone dose.

Rituximab was given to 16 patients as add-on therapy and to six as monotherapy. Overall, 20 (90.9 percent) achieved remission and seven (35 percent) subsequently relapsed. Rituximab treatment led to a significant reduction in 24 hour-proteinuria (p<0.0001), C-reactive protein (p=0.0005), BVAS (p<0.0001) and prednisone dose (p<0.0001). Moreover, eGFR remained stable.

In terms of safety, treatment was well tolerated. There was one patient who died after 60 months of follow-up.

Researchers noted that while the use of rituximab in IgAV may potentially reduce the proliferation of IgA-producing plasma cells or deplete tissue-infiltrating B-cells, “its therapeutic efficacy most likely results from the impairment of other B-cell functions such as antigen-presentation and T-cell costimulation, as already postulated in ANCA-associated vasculitis and other autoimmune conditions.” [Nephrol Dial Transplant 2013;29:1151–59]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
6 days ago
A strong belief in the necessity of medication is associated with better adherence to oral disease-modifying antirheumatic drugs (DMARDs) or prednisone, while higher self-efficacy correlates with poor adherence, in a diverse cohort of patients with rheumatoid arthritis (RA), suggests a study.
5 days ago
Low-dose administrations of haloperidol after thoracic surgery does not appear to prevent postoperative delirium, according to a new study.
3 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 4 days ago
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.